about
Pre-analytical issues in the haemostasis laboratory: guidance for the clinical laboratoriesRisk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis.Assessment of the performances of AcuStar HIT and the combination with heparin-induced multiple electrode aggregometry: a retrospective study.Platelet microparticle generation assay: a valuable test for immune heparin-induced thrombocytopenia diagnosis.Rapid exclusion of the diagnosis of immune HIT by AcuStar HIT and heparin-induced multiple electrode aggregometry.Deficiency in mouse hyaluronidase 2: a new mechanism of chronic thrombotic microangiopathy.Usefulness of Flow Cytometric Mepacrine Uptake/Release Combined with CD63 Assay in Diagnosis of Patients with Suspected Platelet Dense Granule Disorder.Persistent heparin-induced thrombocytopenia: danaparoid cross-reactivity or delayed-onset heparin-induced thrombocytopenia? A case report.Heparin monitoring: clinical outcome and practical approach.Heparin-induced multi-electrode aggregometry method for heparin-induced thrombocytopenia testing: communication from the SSC of the ISTH.Functional Assays in the Diagnosis of Heparin-Induced Thrombocytopenia: A Review.Preventive strategies against bleeding due to nonvitamin K antagonist oral anticoagulants.Management of non-vitamin K antagonist oral anticoagulants in the perioperative settingMeasurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays.EVpedia: a community web portal for extracellular vesicles research.Non-VKA Oral Anticoagulants: Accurate Measurement of Plasma Drug ConcentrationsAssessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature.Dabigatran etexilate and risk of myocardial infarction, other cardiovascular events, major bleeding, and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials.Pathophysiology, diagnosis, and treatment of paroxysmal nocturnal hemoglobinuria: a review.Dose tailoring of dabigatran etexilate: obvious or excessive?Remodeling and Repair in Rhinosinusitis.Tips and tricks for flow cytometry-based analysis and counting of microparticles.Evaluation and optimization of the extended information process unit (E-IPU) validation module integrating the sysmex flag systems and the recommendations of the French-speaking cellular hematology group (GFHC).Microparticle bearing tissue factor: a link between promyelocytic cells and hypercoagulable state.Inhibition of tissue factor pathway inhibitor increases the sensitivity of thrombin generation assay to procoagulant microvesicles.Bioactivity and hemocompatibility study of amorphous hydrogenated carbon coatings produced by pulsed magnetron discharge.Usefulness of thresholds for smear review of neutropenic samples analyzed with a Sysmex XN-10 analyzer.Periprocedural Management of Direct Oral Anticoagulants Should Be Guided by Accurate Laboratory TestsMorphology, cytogenetics, and survival in myelodysplasia with del(20q) or ider(20q): a multicenter study.Pre-analytical issues in the measurement of circulating microparticles: current recommendations and pending questions.A comparison of six major platelet functional tests to assess the impact of carbon nanomaterials on platelet function: a practical guide.No effect of lysis solutions on absolute CD19+ lymphocytes count and CD45 index in chronic lymphocytic leukemia.A GEIL flow cytometry consensus proposal for quantification of plasma cells: application to differential diagnosis between MGUS and myeloma.Additional erythrocytic and reticulocytic parameters helpful for diagnosis of hereditary spherocytosis: results of a multicentre study.Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate.Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide.Impact of the Direct Oral Anticoagulants on Activated Clotting Time.Comparison of five D-dimer reagents and application of an age-adjusted cut-off for the diagnosis of venous thromboembolism in emergency department.Influence of dabigatran and rivaroxaban on routine coagulation assays. A nationwide Belgian survey.Does the Russell Viper Venom time test provide a rapid estimation of the intensity of oral anticoagulation? A cohort study.
P50
Q28076774-44D5E32A-B8DF-44C5-9B77-262929794D9FQ30241189-C6653526-33B9-47CE-8007-FF0899241FFEQ33408683-798A939A-A653-41E5-9029-AE1C12FBD55FQ33412242-B1E96E2D-A34C-4433-B9FD-85479F4CB2A1Q33413076-882452B8-8130-445E-870E-E03CF0D5F16EQ33422493-F76CD36B-AF84-411E-BF88-77398840D854Q33429976-2B848CCE-6333-4663-9E28-54FFDF96BB0EQ33431664-475542A4-9780-4AC5-AAE4-8B8E15DADDD3Q33436800-3FD56BC3-326E-4796-BCF7-91D802EEF950Q33436952-CDC8D317-2497-4D2F-A0A4-98F4FD8E6285Q33440890-C83ABF99-4AD9-4CCB-8448-E2B38F7901B2Q33854667-50B17A0B-177A-4FDF-B298-0A06994DFFCDQ34207558-E1A3ABCD-11B3-4B11-ADC7-326A2C7144ECQ35154142-88ABF7CA-ADCA-44EF-8445-9D77971E46F9Q35221358-4E4BE1F5-022C-40DB-ABE5-9D2EFA79BD69Q35674404-304A8E07-D5AE-4609-8FBD-9D351C7628D8Q38046007-64BDD9F3-ADAE-497A-84F6-E1114471831FQ38218292-8A848D86-8B88-4D7A-8797-A916B71632C2Q38370916-5C6B238E-56E4-4BEA-A3D0-66A9D9133C67Q38494667-018540FD-1D74-4758-9593-3A482A3F2666Q38542580-50DCB506-58F0-4EF0-8E01-328D798C8F72Q38646623-84F8B6B2-E98A-4569-B392-45AD663AD948Q38878190-CA839F46-EC52-4FB7-9113-E2EDC2746778Q39051940-0583E18D-D467-4EF6-96B6-954BC081D6C3Q39133935-9CEAB065-8CB2-4991-954E-17A9F1FEEE52Q39229367-469144EC-0A9D-4F60-B6ED-861741E03A3FQ39369548-D1FC692D-C383-4592-A30D-E949A93DE730Q42378762-3D0FFD3D-DB25-4F31-B849-BAEA80F37043Q44166914-92049E85-210E-446A-89B2-C63D6CA0ECBAQ45885114-B12C29ED-99C3-4F11-9A98-B41F32761145Q46799089-69075DF4-CB3D-4343-BFDA-ADD9C819E4D4Q50533872-2E6C6CE8-7A15-491B-A8BF-543CD9CF3D2EQ50539011-FB5263D6-EF32-405D-B2FF-7F3110DC3EA5Q50550770-85D2461F-4E40-48A3-9A00-A451677827EAQ50893821-57301F78-A7B9-4E7B-9643-9FBCCD7C6BA3Q50909355-AF56AD9E-AA3F-4417-AA4E-B133E3476292Q51046235-D06F8591-965F-4D62-8279-1B0CF2598C21Q51771819-7B6DBA7F-3CCC-41F8-B65F-7682A1DCE2E8Q53154416-EE6C3CA7-ACD3-4A64-89F3-8963B46CBB56Q53298813-A4555A71-DFDB-4FC2-A171-EE3A0F32BADC
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
François Mullier
@ast
François Mullier
@en
François Mullier
@es
François Mullier
@nl
François Mullier
@sl
type
label
François Mullier
@ast
François Mullier
@en
François Mullier
@es
François Mullier
@nl
François Mullier
@sl
prefLabel
François Mullier
@ast
François Mullier
@en
François Mullier
@es
François Mullier
@nl
François Mullier
@sl
P106
P1153
35488466700
P21
P31
P496
0000-0001-6947-6099